Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)

NCT05601700 is registered in ClinicalTrials.gov with Ente Ospedaliero Ospedali Galliera as lead sponsor.

NCT NCT05601700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05601700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)
Lead sponsor
Ente Ospedaliero Ospedali Galliera
Phase
Phase 3
Overall status
Recruiting
Start date
September 22, 2022
Completion date
September 22, 2029
Enrollment
132 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, ovarian epithelial, low grade serous adenocarcinoma of ovary